Human Anti-TNFRSF10B Recombinant Antibody (TAB-203)

Customer Review

There are currently no Customer reviews or questions for TAB-203. Click the button above to contact us or submit your feedback about this product.

Rachel Adams
25.Apr,23

Great for TNFRSF10B Research

The Anti-TNFRSF10B Recombinant Antibody has been excellent for our TNFRSF10B studies. Its quality is top-notch, providing clear and reliable results. This product has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Michael Clark
07.Aug,22

Effective and Dependable

We incorporated this antibody into our TNFRSF10B protocols, and it has been a great asset. The consistency and reliability are impressive, allowing for accurate and reproducible results. The reliable performance has made it an invaluable tool in our lab.

Laura Harris
03.Jun,21

Consistent High-Quality Results

This antibody has proven to be consistent and high-quality in our TNFRSF10B procedures. The reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.

Q&As

1. Is the anti-TNFRSF10B recombinant antibody suitable for use in Western blotting?

   A: Yes, the anti-TNFRSF10B recombinant antibody (TAB-203) is suitable for use in Western blotting. It provides specific binding to TNFRSF10B, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-TNFRSF10B recombinant antibody?

   A: The recommended storage condition for the anti-TNFRSF10B recombinant antibody (TAB-203) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-TNFRSF10B recombinant antibody be used in immunoprecipitation assays?

   A: Yes, the anti-TNFRSF10B recombinant antibody (TAB-203) can be used in immunoprecipitation assays. It provides specific binding to TNFRSF10B, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-TNFRSF10B recombinant antibody effective in ELISA applications?

   A: Yes, the anti-TNFRSF10B recombinant antibody (TAB-203) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of TNFRSF10B.

5. What is the optimal dilution for using the anti-TNFRSF10B recombinant antibody in immunofluorescence?

   A: The optimal dilution for using the anti-TNFRSF10B recombinant antibody (TAB-203) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Wang, Liqin, et al. "cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis." Nature Cancer 3.11 (2022): 1284-1299. https://doi.org/s43018-022-00462-2
   This study investigates the effectiveness of combining cFLIP suppression and DR5 activation to target and eliminate senescent cancer cells. Utilizing CRISPR/Cas9-based genetic screens, researchers identified that senescent cells, which are resistant to apoptosis due to high cFLIP expression, can be sensitized to death by activating DR5 with an agonistic antibody. The study demonstrates that this combination treatment, enhanced by BRD2 inhibition, effectively kills senescent cells and induces a bystander effect, leading to the death of adjacent non-senescent cells in various cancer models.
   Creative Biolabs significantly contributed to this research by supplying critical reagents. The agonistic antibody targeting DR5 (Cat#: TAB-203) and the BRD2 inhibitor provided by Creative Biolabs were instrumental in the study. These reagents enabled the researchers to validate the therapeutic strategy, demonstrating the potential of combining pro-senescence therapy with DR5 activation in cancer treatment.
2. Park, Jong-Sung, et al. "Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma." Nature communications 10.1 (2019): 1128. https://doi.org/10.1038/s41467-019-09101-4
   This research investigates how targeting death receptor 5 (DR5) can reverse fibrosis in scleroderma mouse models. The study reveals that scleroderma progression involves the conversion of resident fibroblasts into myofibroblasts (MFBs) expressing α-smooth muscle actin (α-SMA) with increased capacity to produce collagen and fibrogenic components. The researchers demonstrated that TLY012, an engineered human TNF-related apoptosis-inducing ligand (TRAIL), selectively blocks dermal fibroblast activation and induces DR-mediated apoptosis in α-SMA+ MFBs through upregulated DR5. Significantly, TLY012 reversed established skin fibrosis to near-normal skin architecture in both bleomycin-induced and tight skin-1 (Tsk-1) mouse models of scleroderma.
   Creative Biolabs provided the anti-DR5 agonistic antibody (Conatumumab) and anti-DR4 agonistic antibody (Mapatumumab), which were used to validate the mechanism of DR-mediated apoptosis in myofibroblasts. These antibodies enabled the researchers to demonstrate that DR5, rather than DR4, is predominantly responsible for TLY012-induced apoptosis in activated myofibroblasts. This contribution was essential for establishing that targeting upregulated DR5 in α-SMA+ MFBs represents a viable therapeutic approach for fibrosis in scleroderma, potentially offering a new treatment strategy for this serious autoimmune condition.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-203, RRID: AB_3111871)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Park, Jong-Sung, et al. "Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma." Nature communications 10.1 (2019): 1128.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "TNFRSF10B"

Select a product category from the dropdown menu below to view related products.